Drug intelligence / Profile preview

Jing Su Ke Li

Development stage: Unknown
Lead developer: Chinese Academy of Medical Sciences
Administration: Oral

Overview

Jing Su Ke Li is a Traditional Chinese Medicine (TCM) granule formulation used for the treatment of cervical spondylotic radiculopathy (CSR). Developed and studied by institutions including the Chinese Academy of Medical Sciences and Peking Union Medical College, the drug is designed to alleviate symptoms such as neck pain, numbness, and restricted movement associated with nerve root compression in the cervical spine. Its therapeutic effects are attributed to its multi-herbal composition, which is traditionally used to promote blood circulation, remove blood stasis, and relieve pain. Clinical trials have focused on evaluating its efficacy, safety, and health economics in comparison to placebo for patients suffering from CSR.

Brand names: Jing Su Ke Li
Other names: Jingsu KeliJingsu Granules

Beyond the preview

Go deeper on Jing Su Ke Li.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jing Su Ke Li.

Explore the full profile